Abstract
Cell-based tolerogenic therapy is a promising approach for the treatment of autoimmune diseases and transplant rejection. Regulatory T cells and tolerogenic dendritic cells have been particularly explored in the treatment of various autoimmune disorders in experimental models of disease. Although some of these cells have already been tested in a limited number of clinical trials, there is still a need for preclinical research on tolerogenic cells in animal models of autoimmunity. This review will focus on the relevance of data obtained from studies in experimental animal models for the use of tolerogenic cell-based therapy in humans. Also, perspectives for further improvement of tolerogenic cell preparation towards enhanced suppressive activity and stability of the cells will be discussed.
Keywords: Cell-based tolerogenic therapy, regulatory T cells, tolerogenic dendritic cells, multiple sclerosis, type 1 diabetes, rheumatoid arthritis.
Current Pharmaceutical Design
Title:Cell-based Tolerogenic Therapy, Experience from Animal Models of Multiple Sclerosis, Type 1 Diabetes and Rheumatoid Arthritis
Volume: 23 Issue: 18
Author(s): Ivana Stojanovic, Mirjana Dimitrijevic, Marta Vives-Pi, Maria Jose Mansilla, Irma Pujol-Autonell, Silvia Rodríguez-Fernandez, Lenka Palova-Jelínkova, David P. Funda, Alisa Gruden-Movsesijan, Ljiljana Sofronic-Milosavljevic, Catharien M. U. Hilkens, Eva Martinez Caceres and Djordje Miljkovic*
Affiliation:
- Institute for Biological Research "Sinisa Stankovic", Department of Immunology, Despota Stefana 142, 11000 Belgrade,Serbia
Keywords: Cell-based tolerogenic therapy, regulatory T cells, tolerogenic dendritic cells, multiple sclerosis, type 1 diabetes, rheumatoid arthritis.
Abstract: Cell-based tolerogenic therapy is a promising approach for the treatment of autoimmune diseases and transplant rejection. Regulatory T cells and tolerogenic dendritic cells have been particularly explored in the treatment of various autoimmune disorders in experimental models of disease. Although some of these cells have already been tested in a limited number of clinical trials, there is still a need for preclinical research on tolerogenic cells in animal models of autoimmunity. This review will focus on the relevance of data obtained from studies in experimental animal models for the use of tolerogenic cell-based therapy in humans. Also, perspectives for further improvement of tolerogenic cell preparation towards enhanced suppressive activity and stability of the cells will be discussed.
Export Options
About this article
Cite this article as:
Stojanovic Ivana, Dimitrijevic Mirjana, Vives-Pi Marta, Mansilla Jose Maria, Pujol-Autonell Irma, Rodríguez-Fernandez Silvia, Palova-Jelínkova Lenka, Funda P. David, Gruden-Movsesijan Alisa, Sofronic-Milosavljevic Ljiljana, Hilkens M. U. Catharien, Caceres Martinez Eva and Miljkovic Djordje*, Cell-based Tolerogenic Therapy, Experience from Animal Models of Multiple Sclerosis, Type 1 Diabetes and Rheumatoid Arthritis, Current Pharmaceutical Design 2017; 23 (18) . https://dx.doi.org/10.2174/1381612823666170214120708
DOI https://dx.doi.org/10.2174/1381612823666170214120708 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Updates on Biological Activities of Oxadiazoles
Mini-Reviews in Medicinal Chemistry Novel Therapeutic Approaches in Rheumatoid Arthritis: Role of Janus Kinases Inhibitors
Current Medicinal Chemistry Viral Infection - A Cure for Type 1 Diabetes?
Current Medicinal Chemistry Targeting Heat Shock Protein 90 for Malaria
Mini-Reviews in Medicinal Chemistry The Influence of Diabetes Mellitus on Proliferation and Osteoblastic Differentiation of MSCs
Current Stem Cell Research & Therapy Vascular Endothelial Growth Factor Receptor 1, a Therapeutic Target in Cancer, Inflammation and Other Disorders
Current Medicinal Chemistry n-3 Fatty Acids: Role in Neurogenesis and Neuroplasticity
Current Medicinal Chemistry The Relationship Between Prolidase Activity and Atrial Electromechanical Changes in Patients with Paroxysmal Atrial Fibrillation
Combinatorial Chemistry & High Throughput Screening Catching the Therapeutic Window of Opportunity in Early Crohn`s Disease
Current Drug Targets Use of Topiceuticals (Topically Applied, Peripherally Acting Drugs) in the Treatment of Chronic Pain
Current Drug Therapy Targeting Vascular Changes in Lesions in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
Central Nervous System Agents in Medicinal Chemistry Modulatory Effects of Peroxisome Proliferator-Activated Receptor-γ on CXCR3 Chemokines
Recent Patents on Inflammation & Allergy Drug Discovery Emerging Roles of MicroRNA-22 in Human Disease and Normal Physiology
Current Molecular Medicine Biology and Clinical Relevance of Mannose-Binding Lectin
Drug Design Reviews - Online (Discontinued) p53 Peptide Prevents LITAF-Induced TNF-Alpha-Mediated Mouse Lung Lesions and Endotoxic Shock
Current Molecular Medicine Pharmacotherapies to Manage Bone Loss-Associated Diseases: A Quest for the Perfect Benefit-to-Risk Ratio
Current Medicinal Chemistry Therapeutic Implications of Gene Deletion of Ligands and Receptors of Members of TNF Superfamily
Medicinal Chemistry Reviews - Online (Discontinued) Atherogenic Index of Plasma in Women with Rheumatoid Arthritis and Systemic Lupus Erythematosus: A 10-Year Potential Predictor of Cardiovascular Disease
Current Rheumatology Reviews The Interplay Between Inflammation and Oxidative Stress in Carcinogenesis
Current Molecular Medicine Discovery of Lansoprazole and its Unique Pharmacological Properties Independent from Anti-secretory Activity
Current Pharmaceutical Design